Research Underlying Galectin's Development of GR-MD-02 in Cancer Presented at the Society for Immunotherapy of Cancer Annual Meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
| GALECTIN (NASDAQ: GALT) | Delayed: 3.54 +0.16 (4.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.38 | 52 Week High | $3.05 | |||
| Open | $3.37 | 52 Week Low | $0.49 | |||
| Day High | $3.56 | P/E | N/A | |||
| Day Low | $3.27 | EPS | $-1.32 | |||
| Volume | 141,163 | |||||
